Foscenvivint

DB15034InvestigationalSmall molecule

PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).

Chemical structure of Foscenvivint
Formula / weight
C33H35N6O7P · 658.652 g/mol (avg)
Code names
OP-724 · PRI-724

Resolves to

Compound
UNII43Y934BBZ6CAS1198780-38-9
Structure
InChIKeyVHOZWHQPEJGPCC-AZXNYEMZSA-NSMILESC[C@H]1[C@H]2N([C@@H](CC3=CC=C(OP(O)(O)=O)C=C3)C(=O)N1CC1=CC=CC3=C1N=CC=C3)C(=O)CN(C)N2C(=O)NCC1=CC=CC=C1
Targets
Q92793CREBBP

What you can answer from here — as of May 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Foscenvivint, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In